Study of Difluprednate in the Treatment of Uveitis
Sponsor
Sirion Therapeutics, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT00501579
Collaborator
(none)
1
Study Details
Study Description
Brief Summary
The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
2 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- Diagnosis of endogenous anterior uveitis in at least 1 eye
Exclusion Criteria:
-
Presence of intermediate uveitis, posterior uveitis or panuveitis
-
Corneal abrasion
-
Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease
-
Allergy to similar drugs, such as other corticosteroids
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | John-Kenyon American Eye Institute | New Albany | Indiana | United States | 47150 |
Sponsors and Collaborators
- Sirion Therapeutics, Inc.
Investigators
- Study Chair: Roger Vogel, MD, Sirion Therapeutics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00501579
Other Study ID Numbers:
- ST-601A-001
First Posted:
Jul 16, 2007
Last Update Posted:
Aug 29, 2008
Last Verified:
Aug 1, 2008